Approval · Notice of Compliance 560 · 2002
PHL-GABAPENTIN: Notice of Compliance 560
Issued December 10, 2002
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 560
- Date
- December 10, 2002
- Company
- Pharmel Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Admin
- Reason
- Product name change from gabapentin
- Therapeutic class
- Antiepileptic agent
- Canadian reference product
- NEURONTIN
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| PHL-GABAPENTIN | 02246314 | Marketed |
| PHL-GABAPENTIN | 02246315 | Marketed |
| PHL-GABAPENTIN | 02246316 | Marketed |
Medicinal ingredients
- GABAPENTIN 100 MG per TAB
- GABAPENTIN 300 MG per TAB
- GABAPENTIN 400 MG per TAB